CN109937037A - 用于治疗某些泌尿疾病的il-8抑制剂 - Google Patents

用于治疗某些泌尿疾病的il-8抑制剂 Download PDF

Info

Publication number
CN109937037A
CN109937037A CN201880003982.6A CN201880003982A CN109937037A CN 109937037 A CN109937037 A CN 109937037A CN 201880003982 A CN201880003982 A CN 201880003982A CN 109937037 A CN109937037 A CN 109937037A
Authority
CN
China
Prior art keywords
inhibitor
use according
compound
pharmaceutical composition
active compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880003982.6A
Other languages
English (en)
Chinese (zh)
Inventor
M·阿莱格雷蒂
A·阿拉米尼
M·C·切斯塔
G·比安基尼
L·布兰多利尼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dong Pei Pharmaceutical Co Ltd
Original Assignee
Dong Pei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dong Pei Pharmaceutical Co Ltd filed Critical Dong Pei Pharmaceutical Co Ltd
Publication of CN109937037A publication Critical patent/CN109937037A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201880003982.6A 2017-01-03 2018-01-02 用于治疗某些泌尿疾病的il-8抑制剂 Pending CN109937037A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17150176.0 2017-01-03
EP17150176.0A EP3342407A1 (en) 2017-01-03 2017-01-03 Il-8 inihibitors for use in the treatment of some urological disorders
PCT/EP2018/050009 WO2018127469A1 (en) 2017-01-03 2018-01-02 Il-8 inihibitors for use in the treatment of some urological disorders

Publications (1)

Publication Number Publication Date
CN109937037A true CN109937037A (zh) 2019-06-25

Family

ID=57758480

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880003982.6A Pending CN109937037A (zh) 2017-01-03 2018-01-02 用于治疗某些泌尿疾病的il-8抑制剂

Country Status (14)

Country Link
US (1) US20190336484A1 (https=)
EP (2) EP3342407A1 (https=)
JP (1) JP2020503267A (https=)
KR (1) KR20190102177A (https=)
CN (1) CN109937037A (https=)
AU (1) AU2018206134A1 (https=)
BR (1) BR112019009588A2 (https=)
CA (1) CA3046531A1 (https=)
EA (1) EA201991357A1 (https=)
IL (1) IL267577A (https=)
MA (1) MA47199A (https=)
MX (1) MX2019007972A (https=)
WO (1) WO2018127469A1 (https=)
ZA (1) ZA201902427B (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3868368A1 (en) * 2020-02-21 2021-08-25 Dompe' Farmaceutici S.P.A. Cxcl8 (interleukin-8) activity inhibitor and corticosteroid combination and pharmaceutical composition and use thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015687A1 (en) * 1999-08-27 2001-03-08 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
WO2010031835A2 (en) * 2008-09-18 2010-03-25 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
US20120076791A1 (en) * 2010-09-29 2012-03-29 Philip Bosch Methods Of Treating Chronic Prostatitis/Chronic Pelvic Pain Syndrome
CN105582136A (zh) * 2014-09-12 2016-05-18 青岛华之草医药科技有限公司 一种中药提取物在制备治疗前列腺炎的药物中的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1776336T3 (pl) 2004-03-23 2010-06-30 Dompe Farm Spa Pochodne kwasu 2-fenylopropionowego i zawierające je kompozycje farmaceutyczne
WO2010078403A2 (en) 2008-12-30 2010-07-08 Lipella Pharmaceuticals Inc. Methods and compositions for diagnosing urological disorders
EP3117835A1 (en) * 2015-07-14 2017-01-18 Dompé farmaceutici s.p.a. Il-8 inhibitors for use in the treatment of certain urological disorders

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001015687A1 (en) * 1999-08-27 2001-03-08 Merck & Co., Inc. Method for treating or preventing chronic prostatitis or chronic pelvic pain syndrome
WO2010031835A2 (en) * 2008-09-18 2010-03-25 Dompe' S.P.A. 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them
US20120076791A1 (en) * 2010-09-29 2012-03-29 Philip Bosch Methods Of Treating Chronic Prostatitis/Chronic Pelvic Pain Syndrome
CN105582136A (zh) * 2014-09-12 2016-05-18 青岛华之草医药科技有限公司 一种中药提取物在制备治疗前列腺炎的药物中的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
贺大林等: "前列腺按摩液中IL-8和TNF-α测定在慢性前列腺炎诊断、分型中的临床意义", 《中华男科学杂志》 *

Also Published As

Publication number Publication date
WO2018127469A1 (en) 2018-07-12
IL267577A (en) 2019-08-29
KR20190102177A (ko) 2019-09-03
MX2019007972A (es) 2019-09-09
EP3342407A1 (en) 2018-07-04
MA47199A (fr) 2019-11-13
JP2020503267A (ja) 2020-01-30
BR112019009588A2 (pt) 2019-08-06
EA201991357A1 (ru) 2019-12-30
CA3046531A1 (en) 2018-07-12
AU2018206134A1 (en) 2019-05-23
EP3565545A1 (en) 2019-11-13
US20190336484A1 (en) 2019-11-07
ZA201902427B (en) 2020-08-26

Similar Documents

Publication Publication Date Title
Fang et al. Treatment with celastrol protects against obesity through suppression of galanin-induced fat intake and activation of PGC-1α/GLUT4 axis-mediated glucose consumption
Xie et al. Costunolide improved dextran sulfate sodium-induced acute ulcerative colitis in mice through NF-κB, STAT1/3, and Akt signaling pathways
US20250032461A1 (en) Il-8 inihibitors for use in the treatment of some urological disorders
JP2017128578A (ja) 腎疾患の治療におけるモノおよびジカルボン酸のアミドの使用
JP2023126760A (ja) 抗炎症剤
US9937173B2 (en) Method of treating obesity
Ros-Madrid et al. Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective
CN110167545A (zh) 吉非罗齐对晚期婴儿型神经元蜡样质脂褐质沉积症患者寿命的增加和自发活动的改善
KR20150138225A (ko) 항당뇨병성 및 다른 유용한 활성을 갖는 식물 추출물
CN109937037A (zh) 用于治疗某些泌尿疾病的il-8抑制剂
CN111093661A (zh) 戊二酰亚胺衍生物用于治疗与细胞因子的异常活性相关的疾病的用途
WO2022048618A1 (en) Methods to treat inflammatory bowel disease
JP2020536929A (ja) Ｃｃｒ３阻害剤を用いた、そう痒症、乾皮症、及び関連疾患を治療するための方法及び組成物
TW201212912A (en) Sulfoxide compounds, method of generation and pharmaceutical uses thereof
HK1247853B (en) Il-8 inhibitors for use in the treatment of certain urological disorders
JP2026046075A (ja) 細胞性粘菌由来分化誘導因子を含む皮膚線維化疾患の予防または治療のための局所塗布剤
BR112018000676B1 (pt) Inibidores de il-8, composição farmacêutica, produto ou kit para o uso e uso de um inibidor de il-8
HK40028225A (en) Use of a glutarimide derivative to treat diseases related to the aberrant activity of cytokines

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20190625

WD01 Invention patent application deemed withdrawn after publication